Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead

Nerve agents (NAs) are extremely neurotoxic synthetic organophosphate (OP) compounds exploited as weapons of mass destruction in terrorist attacks and chemical warfare. Considering the current world scenario, there is a persistent threat of NA-exposure to military personals and civilians. Various prophylactic and post-exposure treatments (such as atropine and oximes) available currently for NA-poisoning are inadequate and unsatisfactory and suffer from severe limitations. Hence, developing safe and effective treatment(s) against NA-poisoning is a critical necessity. With regards to counteracting NA-toxicity, the OP-hydrolyzing enzymes (OPHEs), which can hydrolyze and inactivate a variety of NAs, have emerged as promising candidates for the development of prophylactic therapy against NA-poisoning. However, there are many hurdles to be crossed before these enzymes can be brought to therapeutic use in humans. In this article, we have reviewed the various advancements in the field of development of OPHEs as prophylactic against NA-poisoning. The article majorly focuses on the toxic effects of NAs, various available therapies to counteract NA poisoning, the current status of OPHEs and attempts made to improve the various properties of these enzymes. Further, we have also briefly discussed about the prospective work that is needed to be undertaken for developing these OPHEs into those suitable for use in humans.

[1]  Tetsuya Hayashi,et al.  Escherichia coli , 1983, CABI Compendium.

[2]  Jan Brezovsky,et al.  Computational tools for designing and engineering enzymes. , 2014, Current opinion in chemical biology.

[3]  F. Raushel,et al.  Catalytic mechanisms for phosphotriesterases. , 2013, Biochimica et biophysica acta.

[4]  S. Hoenig.  Comprar Compendium of Chemical Warfare Agents | Hoenig, Steven L. | 9780387346267 | Springer , 2007 .

[5]  A. Pande,et al.  Improving storage stability of recombinant organophosphorus hydrolase. , 2015, Protein expression and purification.

[6]  F. Worek,et al.  Catalytic bioscavengers in nerve agent poisoning: A promising approach? , 2016, Toxicology letters.

[7]  C. Aaron,et al.  Organophosphate and carbamate poisoning. , 2015, Emergency medicine clinics of North America.

[8]  Yang Liu,et al.  Enzyme therapeutics for systemic detoxification. , 2015, Advanced drug delivery reviews.

[9]  Dan S. Tawfik,et al.  Enhanced stereoselective hydrolysis of toxic organophosphates by directly evolved variants of mammalian serum paraoxonase , 2006, The FEBS journal.

[10]  J. Defrank,et al.  Purification and properties of an organophosphorus acid anhydrase from a halophilic bacterial isolate , 1991, Journal of bacteriology.

[11]  A. Pande,et al.  Interplay between amino acid residues at positions 192 and 115 in modulating hydrolytic activities of human paraoxonase 1. , 2014, Biochimie.

[12]  B. P. Doctor,et al.  Crossroads in the evaluation of paraoxonase 1 for protection against nerve agent and organophosphate toxicity. , 2012, Toxicology letters.

[13]  P. Masson.  Evolution of and perspectives on therapeutic approaches to nerve agent poisoning. , 2011, Toxicology letters.

[14]  Giuseppe Manco,et al.  Improving the promiscuous nerve agent hydrolase activity of a thermostable archaeal lactonase. , 2010, Bioresource technology.

[15]  A Mulchandani,et al.  Biosensor for direct determination of organophosphate nerve agents using recombinant Escherichia coli with surface-expressed organophosphorus hydrolase. 1. Potentiometric microbial electrode. , 1998, Analytical chemistry.

[16]  M. Maroni,et al.  Organophosphorous compounds. , 1994, Toxicology.

[17]  J. Stewart,et al.  A comparison of the efficacy of HI6 and 2-PAM against soman, tabun, sarin, and VX in the rabbit. , 1994, Toxicology letters.

[18]  S. Nurulain.  Efficacious Oxime for Organophosphorus Poisoning: A Minireview , 2011 .

[19]  P. Masson,et al.  Progress in the development of enzyme-based nerve agent bioscavengers. , 2013, Chemico-biological interactions.

[20]  Florence Demenais,et al.  Association of Forced Vital Capacity with the Developmental Gene NCOR2 , 2016, PloS one.

[21]  F. Raushel,et al.  Characterization of the zinc binding site of bacterial phosphotriesterase. , 1992, The Journal of biological chemistry.

[22]  Wilfred Chen,et al.  Functional analysis of organophosphorus hydrolase variants with high degradation activity towards organophosphate pesticides. , 2006, Protein engineering, design & selection : PEDS.

[23]  F. Worek,et al.  Chromatographic preparation and kinetic analysis of interactions between tabun enantiomers and acetylcholinesterase. , 2010, Toxicology letters.

[24]  A. Pande,et al.  Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli. , 2015, Protein expression and purification.

[25]  Bb Hoffman.  Neurotransmission: The autonomic and somatic motor nervous systems , 1996 .

[26]  S. Gwaltney,et al.  Novel nucleophiles enhance the human serum paraoxonase 1 (PON1)-mediated detoxication of organophosphates. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[27]  I. Petrikovics,et al.  Nano-Intercalated Organophosphorus-Hydrolyzing Enzymes in Organophosphorus Antagonism , 2012, AAPS PharmSciTech.

[28]  M. Eddleston,et al.  Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials. , 2002, QJM : monthly journal of the Association of Physicians.

[29]  P. M. Legler,et al.  Development of organophosphate hydrolase activity in a bacterial homolog of human cholinesterase , 2014, Front. Chem..

[30]  P. Taylor,et al.  Mutation of acetylcholinesterase to enhance oxime-assisted catalytic turnover of methylphosphonates. , 2007, Toxicology.

[31]  S. Chakraborti,et al.  Crystal structure of human senescence marker protein 30: insights linking structural, enzymatic, and physiological functions . , 2010, Biochemistry.

[32]  R. B. Pringle,et al.  The effect of PON1 enhancers on reducing acetylcholinesterase inhibition following organophosphate anticholinesterase exposure in rats. , 2015, Toxicology.

[33]  J. Kassa.  Therapeutic and neuroprotective efficacy of pharmacological pretreatment and antidotal treatment of acute tabun or soman poisoning with the emphasis on pretreatment drug PANPAL. , 2006, Arhiv za higijenu rada i toksikologiju.

[34]  Dan S. Tawfik,et al.  Engineering V-type nerve agents detoxifying enzymes using computationally focused libraries. , 2013, ACS chemical biology.

[35]  Germán L. Rosano,et al.  Recombinant protein expression in Escherichia coli: advances and challenges , 2014, Front. Microbiol..

[36]  A. Pande,et al.  Human Paraoxonase 1 as a Pharmacologic Agent: Limitations and Perspectives , 2014, TheScientificWorldJournal.

[37]  B. P. Doctor,et al.  Novel approaches to medical protection against chemical warfare nerve agents. , 2008 .

[38]  Dan S. Tawfik,et al.  Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes , 2004, Nature Structural &Molecular Biology.

[39]  F. Raushel,et al.  Stereoselective hydrolysis of organophosphate nerve agents by the bacterial phosphotriesterase. , 2010, Biochemistry.

[40]  E. Albuquerque,et al.  Effectiveness of Donepezil, Rivastigmine, and (±)Huperzine A in Counteracting the Acute Toxicity of Organophosphorus Nerve Agents: Comparison with Galantamine , 2009, Journal of Pharmacology and Experimental Therapeutics.

[41]  Tatyana Belinskaya,et al.  In vitro characterization of organophosphorus compound hydrolysis by native and recombinant human prolidase. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[42]  M. Balali-Mood,et al.  Clinical Management of Organophosphorus Nerve Agents’ Poisonings , 2014 .

[43]  F. Raushel,et al.  Enhanced degradation of chemical warfare agents through molecular engineering of the phosphotriesterase active site. , 2003, Journal of the American Chemical Society.

[44]  E. Bloch-Shilderman,et al.  Subchronic exposure to low-doses of the nerve agent VX: physiological, behavioral, histopathological and neurochemical studies. , 2008, Toxicology and applied pharmacology.

[45]  W. T. Beaudry,et al.  Enzymatic Hydrolysis of the Chemical Warfare Agent VX and its Neurotoxic Analogues by Organophosphorus Hydrolase , 1997 .

[46]  Andres F Zuluaga,et al.  Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics , 2009, BMC clinical pharmacology.

[47]  F. Baneyx,et al.  Recombinant protein folding and misfolding in Escherichia coli , 2004, Nature Biotechnology.

[48]  T. Hey,et al.  Half‐Life Extension through HESylation® , 2012 .

[49]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2014 , 2014, Nature Biotechnology.

[50]  P. Masson,et al.  Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo , 2013, Proceedings of the National Academy of Sciences.

[51]  K. Gill,et al.  Neurotoxicity of Organophosphates and Carbamates , 2011 .

[52]  F. Raushel,et al.  Three-dimensional structure of the zinc-containing phosphotriesterase with the bound substrate analog diethyl 4-methylbenzylphosphonate. , 1996, Biochemistry.

[53]  G. Gellissen.  Production of recombinant proteins : novel microbial and eukaryotic expression systems , 2004 .

[54]  E. Albuquerque,et al.  Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents , 2006, Proceedings of the National Academy of Sciences.

[55]  Corey J Wilson,et al.  Rational protein design: developing next-generation biological therapeutics and nanobiotechnological tools. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[56]  K. D. Tripathi,et al.  Essentials of Medical Pharmacology , 2004 .

[57]  M. Wales,et al.  Organophosphorus hydrolase as an in vivo catalytic nerve agent bioscavenger. , 2012, Drug testing and analysis.

[58]  F. Worek,et al.  Drug development for the management of organophosphorus poisoning , 2013, Expert opinion on drug discovery.

[59]  E. Albuquerque,et al.  Animal Models That Best Reproduce the Clinical Manifestations of Human Intoxication with Organophosphorus Compounds , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[60]  Tamara C. Otto,et al.  Assessing protection against OP pesticides and nerve agents provided by wild-type HuPON1 purified from Trichoplusia ni larvae or induced via adenoviral infection. , 2013, Chemico-biological interactions.

[61]  B. Calesnick,et al.  Human toxicity of various oximes. 2-Pyridine aldoxime methyl chloride, its methane sulfonate salt, and 1,1'-trimethylenebis-(4-formylpyridinium chloride). , 1967, Archives of environmental health.

[62]  E. Albuquerque,et al.  Multiple actions of anticholinesterase agents on chemosensitive synapses: molecular basis for prophylaxis and treatment of organophosphate poisoning. , 1985, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[63]  Dan S. Tawfik,et al.  High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. , 2005, Biochemistry.

[64]  O. Mazor,et al.  Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. , 2015, Bioconjugate chemistry.

[65]  T. Marrs.  The Role of Diazepam in the Treatment of Nerve Agent Poisoning in a Civilian Population , 2004, Toxicological reviews.

[66]  H. Soreq,et al.  Transgenic plants as a source for the bioscavenging enzyme, human butyrylcholinesterase. , 2010, Plant biotechnology journal.

[67]  D. Rochu,et al.  Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. , 2007, Toxicology.

[68]  E. Duysen,et al.  Resistance to organophosphorus agent toxicity in transgenic mice expressing the G117H mutant of human butyrylcholinesterase. , 2004, Toxicology and applied pharmacology.

[69]  J. Mikler,et al.  Chromatographic resolution, characterisation and quantification of VX enantiomers in hemolysed swine blood samples. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[70]  Susanne Hostrup,et al.  Recent trends in stabilising peptides and proteins in pharmaceutical formulation – considerations in the choice of excipients , 2009, Expert opinion on drug delivery.

[71]  S. Schmidt.  Fusion Proteins for Half‐Life Extension , 2013 .

[72]  G. Manco,et al.  Structural determinants of the high thermal stability of SsoPox from the hyperthermophilic archaeon Sulfolobus solfataricus , 2009, Extremophiles.

[73]  P. Taylor,et al.  Oxime-assisted Acetylcholinesterase Catalytic Scavengers of Organophosphates That Resist Aging* , 2011, The Journal of Biological Chemistry.

[74]  Balancing the stability and the catalytic specificities of OP hydrolases with enhanced V-agent activities. , 2008, Protein engineering, design & selection : PEDS.

[75]  Gholamreza Farnoosh,et al.  A Review on Engineering of Organophosphorus Hydrolase (OPH) Enzyme , 2014 .

[76]  E. Clarkson,et al.  Butyrylcholinesterase as a therapeutic drug for protection against percutaneous VX. , 2010, Chemico-biological interactions.

[77]  Hak-Sung Kim,et al.  Rational design of organophosphorus hydrolase with high catalytic efficiency for detoxifying a V-type nerve agent. , 2014, Biochemical and biophysical research communications.

[78]  M. Elias,et al.  Characterisation of the organophosphate hydrolase catalytic activity of SsoPox , 2012, Scientific Reports.

[79]  J. Kang,et al.  Enhanced activity and stability of organophosphorus hydrolase via interaction with an amphiphilic polymer. , 2014, Chemical communications.

[80]  M. Balali-Mood,et al.  Recent Advances in the Treatment of Organophosphorous Poisonings , 2012, Iranian journal of medical sciences.

[81]  Dan S. Tawfik,et al.  Post-exposure treatment of VX poisoned guinea pigs with the engineered phosphotriesterase mutant C23: a proof-of-concept study. , 2014, Toxicology letters.

[82]  W. Strohl.  Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters , 2015, BioDrugs.

[83]  J. Grimsley,et al.  Improved pharmacokinetics and immunogenicity profile of organophosphorus hydrolase by chemical modification with polyethylene glycol. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[84]  G. Larsson,et al.  Characterisation of the Escherichia coli membrane structure and function during fedbatch cultivation , 2004, Microbial cell factories.

[85]  Tatyana Belinskaya,et al.  In search of a catalytic bioscavenger for the prophylaxis of nerve agent toxicity. , 2010, Chemico-biological interactions.

[86]  R. K. Gordon,et al.  Inhibition of guinea pig hemi-diaphragm acetylcholinesterase activity by pyridostigmine bromide and protection against soman toxicity. , 2005, Chemico-Biological Interactions.

[87]  R. Stevens,et al.  Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning , 2008, Proceedings of the National Academy of Sciences.

[88]  L. Novotný,et al.  Organophosphate hydrolases as catalytic bioscavengers of organophosphorus nerve agents. , 2011, Toxicology letters.

[89]  Dan S. Tawfik,et al.  Efficacy of the rePON1 mutant IIG1 to prevent cyclosarin toxicity in vivo and to detoxify structurally different nerve agents in vitro , 2014, Archives of Toxicology.

[90]  B. Singh,et al.  Organophosphorus-degrading bacteria: ecology and industrial applications , 2009, Nature Reviews Microbiology.

[91]  S. Singh,et al.  Solubilization and refolding of bacterial inclusion body proteins. , 2005, Journal of bioscience and bioengineering.

[92]  K. Kuča,et al.  Interaction of nerve agent antidotes with cholinergic systems. , 2010, Current medicinal chemistry.

[93]  K. Kuča,et al.  Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. , 2009, Current medicinal chemistry.

[94]  S. Harvey,et al.  Rational Enzyme Design: Computer Modeling and Site-directed Mutagenesis for the Modification of Catalytic Specificity in Organophosphorus Hydrolase , 1996, CHIMIA.

[95]  D. Ollis,et al.  Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey. , 2010, Biochemical pharmacology.

[96]  S. Langermann,et al.  Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning , 2007, Proceedings of the National Academy of Sciences.

[97]  D. Rochu,et al.  Catalytic Bioscavengers Against Toxic Esters, an Alternative Approach for Prophylaxis and Treatments of Poisonings , 2009, Acta naturae.

[98]  F. Raushel,et al.  Variants of Phosphotriesterase for the Enhanced Detoxification of the Chemical Warfare Agent VR. , 2015, Biochemistry.

[99]  Ramanathan Nagarajan,et al.  Enhancing enzyme stability by construction of polymer-enzyme conjugate micelles for decontamination of organophosphate agents. , 2014, Biomacromolecules.

[100]  Wilfred Chen,et al.  Altering the Substrate Specificity of Organophosphorus Hydrolase for Enhanced Hydrolysis of Chlorpyrifos , 2004, Applied and Environmental Microbiology.

[101]  A. Grunden,et al.  Hydrolysis of organophosphorus compounds by microbial enzymes , 2010, Applied Microbiology and Biotechnology.

[102]  J. Chaudhuri,et al.  Protein folding in vivo and renaturation of recombinant proteins from inclusion bodies , 1996, Molecular biotechnology.

[103]  F. Raushel,et al.  Enzymes for the homeland defense: optimizing phosphotriesterase for the hydrolysis of organophosphate nerve agents. , 2012, Biochemistry.

[104]  B. Schoenborn,et al.  Rapid determination of hydrogen positions and protonation states of diisopropyl fluorophosphatase by joint neutron and X-ray diffraction refinement , 2009, Proceedings of the National Academy of Sciences.

[105]  Y. Ashani,et al.  Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. , 1993, Biochemical pharmacology.

[106]  N. Viguié,et al.  Enzymes hydrolyzing organophosphates as potential catalytic scavengers against organophosphate poisoning , 1998, Journal of Physiology-Paris.

[107]  N. Ferrer-Miralles,et al.  General introduction: recombinant protein production and purification of insoluble proteins. , 2015, Methods in molecular biology.

[108]  A. Grunden,et al.  Improving the catalytic activity of hyperthermophilic Pyrococcus prolidases for detoxification of organophosphorus nerve agents over a broad range of temperatures , 2010, Applied Microbiology and Biotechnology.

[109]  Hee-Ju Nah,et al.  Precise cloning and tandem integration of large polyketide biosynthetic gene cluster using Streptomyces artificial chromosome system , 2015, Microbial Cell Factories.

[110]  Michael Eddleston,et al.  Management of acute organophosphorus pesticide poisoning , 2008, The Lancet.

[111]  B. P. Doctor,et al.  Demonstration of in vivo stability and lack of immunogenicity of a polyethyleneglycol-conjugated recombinant CHO-derived butyrylcholinesterase bioscavenger using a homologous macaque model. , 2010, Chemico-biological interactions.

[112]  D. Rochu,et al.  Preparation and characterization of methoxy polyethylene glycol-conjugated phosphotriesterase as a potential catalytic bioscavenger against organophosphate poisoning. , 2010, Chemico-biological interactions.

[113]  Naoki Masuda,et al.  Sarin poisoning in Tokyo subway , 1995, The Lancet.

[114]  L. Lumley,et al.  Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. , 2007, Toxicology.

[115]  Saumil S. Shah,et al.  Structural insights into the dual activities of the nerve agent degrading organophosphate anhydrolase/prolidase. , 2010, Biochemistry.

[116]  L. A. Palomares,et al.  Production of recombinant proteins: challenges and solutions. , 2004, Methods in molecular biology.

[117]  F. Raushel,et al.  Molecular engineering of organophosphate hydrolysis activity from a weak promiscuous lactonase template. , 2013, Journal of the American Chemical Society.

[118]  J. Defrank,et al.  Hydrolysis of Organophosphorus Compounds by Bacterial Prolidases , 2000 .

[119]  P. Aebersold.  FDA Experience with Medical Countermeasures under the Animal Rule , 2011, Advances in preventive medicine.

[120]  M. Barba,et al.  Spinal Fusion in the Next Generation: Gene and Cell Therapy Approaches , 2014, TheScientificWorldJournal.

[121]  S. L. Mayo,et al.  Nerve Agent Hydrolysis Activity Designed into a Human Drug Metabolism Enzyme , 2011, PloS one.

[122]  Dan S. Tawfik,et al.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes , 2009, BMC clinical pharmacology.

[123]  J. Troyer,et al.  Post-exposure therapy with recombinant human BuChE following percutaneous VX challenge in guinea-pigs. , 2011, Toxicology letters.

[124]  Aurélie Hermant,et al.  A high-throughput protein refolding screen in 96-well format combined with design of experiments to optimize the refolding conditions. , 2011, Protein expression and purification.

[125]  H. Rüterjans,et al.  High-yield expression, purification, and characterization of the recombinant diisopropylfluorophosphatase from Loligo vulgaris. , 2001, Protein expression and purification.

[126]  David C. Davis,et al.  Purification and characterization of functional human paraoxonase-1 expressed in Trichoplusia ni larvae. , 2010, Chemico-biological interactions.

[127]  J. E. Villafranca,et al.  Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid-β-Mediated Deregulation of Estradiol , 2011, PloS one.

[128]  B. P. Doctor,et al.  Bioscavengers for the protection of humans against organophosphate toxicity. , 2005, Chemico-biological interactions.

[129]  D. Cerasoli,et al.  An in vitro and in vivo evaluation of the efficacy of recombinant human liver prolidase as a catalytic bioscavenger of chemical warfare nerve agents , 2015, Drug and chemical toxicology.

[130]  Brian M. Murphy,et al.  Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.

[131]  D. O'Hagan.  Pyrrole, pyrrolidine, pyridine, piperidine and tropane alkaloids. , 2001, Natural product reports.

[132]  H. X. Wang,et al.  [Refolding of recombinant proteins in vitro]. , 1998, Sheng li ke xue jin zhan [Progress in physiology].

[133]  A. Sangamwar,et al.  Toward Understanding the Catalytic Mechanism of Human Paraoxonase 1: Site-Specific Mutagenesis at Position 192 , 2016, PloS one.

[134]  Y. Ashani,et al.  Prophylaxis against organophosphate poisoning by an enzyme hydrolysing organophosphorus compounds in mice. , 1991, Life sciences.

[135]  D. Siddavattam,et al.  A fluorescence based assay with pyranine labeled hexa-histidine tagged organophosphorus hydrolase (OPH) for determination of organophosphates , 2012 .

[136]  Ursula Rinas,et al.  Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins , 2004, Microbial cell factories.

[137]  Y. Kivshar,et al.  Wide-band negative permeability of nonlinear metamaterials , 2012, Scientific Reports.

[138]  J. Buchner,et al.  Refolding of inclusion body proteins. , 2004, Methods in molecular medicine.

[139]  M. Jokanović,et al.  Neurotoxic effects in patients poisoned with organophosphorus pesticides. , 2010, Environmental toxicology and pharmacology.

[140]  Rupa Iyer,et al.  Developments in alternative treatments for organophosphate poisoning. , 2015, Toxicology letters.

[141]  S. Harvey,et al.  Purification and Properties of a Highly Active Organophosphorus Acid Anhydrolase from Alteromonas undina , 1993, Applied and environmental microbiology.

[142]  D. Cerasoli,et al.  Investigation of Evolved Paraoxonase-1 Variants for Prevention of Organophosphorous Pesticide Compound Intoxication , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[143]  W. Kernohan,et al.  Interventions for prevention of bullying in the workplace. , 2012, The Cochrane database of systematic reviews.

[144]  H. P. Sørensen,et al.  Advanced genetic strategies for recombinant protein expression in Escherichia coli. , 2005, Journal of biotechnology.

[145]  A Mulchandani,et al.  Biosensor for direct determination of organophosphate nerve agents. 1. Potentiometric enzyme electrode. , 1999, Biosensors & bioelectronics.

[146]  S. Fujishima,et al.  Sarin poisoning in Tokyo subway , 1995, The Lancet.

[147]  H. Soreq,et al.  Plant‐derived human acetylcholinesterase‐R provides protection from lethal organophosphate poisoning and its chronic aftermath , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[148]  Joel L Sussman,et al.  Directed evolution of hydrolases for prevention of G-type nerve agent intoxication. , 2011, Nature chemical biology.

[149]  Marco Maroni,et al.  Chapter 3 Organophosphorous compounds , 1994 .

[150]  A. Guidotti,et al.  Acute imidazenil treatment after the onset of DFP-induced seizure is more effective and longer lasting than midazolam at preventing seizure activity and brain neuropathology. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[151]  D. Grob,et al.  Poisoning due to organophosphate insecticides. Acute and chronic manifestations. , 1971, The American journal of medicine.

[152]  H. Benschop,et al.  Nerve agent stereoisomers: analysis, isolation and toxicology , 1988 .

[153]  J. McDonough,et al.  Time-dependent reduction in the anticonvulsant effectiveness of diazepam against soman-induced seizures in guinea pigs , 2010, Drug and chemical toxicology.

[154]  Saumil S. Shah,et al.  In vitro release of organophosphorus acid anhydrolase from functionalized mesoporous silica against nerve agents. , 2012, Analytical biochemistry.

[155]  A. Pande,et al.  Stabilization Studies on Bacterially Produced Human Paraoxonase 1 for Improving Its Shelf Life , 2014, Applied Biochemistry and Biotechnology.

[156]  P. Aas,et al.  Choice of approaches in developing novel medical countermeasures for nerve agent poisoning. , 2014, Neurotoxicology.

[157]  F. Baneyx.  Recombinant protein expression in Escherichia coli. , 1999, Current opinion in biotechnology.

[158]  Yong Hwan Kim,et al.  Rational design of paraoxonase 1 (PON1) for the efficient hydrolysis of organophosphates. , 2015, Chemical communications.

[159]  B. Bahnson,et al.  Human paraoxonase double mutants hydrolyze V and G class organophosphorus nerve agents. , 2013, Chemico-biological interactions.

[160]  Frank G Walter,et al.  Toxic industrial chemicals and chemical weapons: exposure, identification, and management by syndrome. , 2015, Emergency medicine clinics of North America.

[161]  F. Löhr,et al.  Binding of a designed substrate analogue to diisopropyl fluorophosphatase: implications for the phosphotriesterase mechanism. , 2006, Journal of the American Chemical Society.

[162]  H. Benschop,et al.  Isolation, anticholinesterase properties, and acute toxicity in mice of the four stereoisomers of the nerve agent soman. , 1984, Toxicology and applied pharmacology.

[163]  Lei Sun,et al.  Crystal structure of methyl parathion hydrolase from Pseudomonas sp. WBC-3. , 2005, Journal of molecular biology.

[164]  R. Kernchen.  Enzyme Stabilization in Nanostructured Materials, for Use in Organophosphorus Nerve Agent Detoxification and Prophylaxis , 2011 .

[165]  F. Raushel,et al.  Stereoselective detoxification of chiral sarin and soman analogues by phosphotriesterase. , 2001, Bioorganic & medicinal chemistry.

[166]  E. Efremenko,et al.  Refolding of hexahistidine-tagged organophophorous hydrolase from inclusion bodies , 2007 .

[167]  Esther Vázquez,et al.  Bacterial inclusion bodies: making gold from waste. , 2012, Trends in biotechnology.

[168]  M. Prostran,et al.  Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. , 2009, Current medicinal chemistry.

[169]  B. Falsini,et al.  Neurotrophin Family Members as Neuroprotectants in Retinal Degenerations , 2014, BioDrugs.

[170]  E Schwarz,et al.  Advances in refolding of proteins produced in E. coli. , 1998, Current opinion in biotechnology.

[171]  F. Raushel,et al.  Augmented Hydrolysis of Diisopropyl Fluorophosphate in Engineered Mutants of Phosphotriesterase* , 1997, The Journal of Biological Chemistry.

[172]  F. Raushel,et al.  Mechanism for the hydrolysis of organophosphates by the bacterial phosphotriesterase. , 2004, Biochemistry.

[173]  S. Schmidt,et al.  Fusion protein technologies for biopharmaceuticals : applications and challenges , 2013 .

[174]  N. Buckley,et al.  Oximes for acute organophosphate pesticide poisoning. , 2011, The Cochrane database of systematic reviews.

[175]  G. Jarvik,et al.  Paraoxonase 1 (PON1) status and substrate hydrolysis. , 2009, Toxicology and applied pharmacology.

[176]  D. Schofield,et al.  Generation of a mutagenized organophosphorus hydrolase for the biodegradation of the organophosphate pesticides malathion and demeton‐S , 2010, Journal of applied microbiology.

[177]  A. Pande,et al.  Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme , 2013, Protein science : a publication of the Protein Society.

[178]  F. Raushel,et al.  Substrate and stereochemical specificity of the organophosphorus acid anhydrolase from Alteromonas sp. JD6.5 toward p-nitrophenyl phosphotriesters. , 2000, Bioorganic & medicinal chemistry letters.

[179]  T. Letzel,et al.  In vitro and in vivo efficacy of PEGylated diisopropyl fluorophosphatase (DFPase). , 2012, Drug testing and analysis.

[180]  G. Fritzsch,et al.  Statistical analysis of crystallographic data obtained from squid ganglion DFPase at 0.85 A resolution. , 2003, Acta crystallographica. Section D, Biological crystallography.

[181]  A. Shafferman,et al.  Stereoselectivity toward VX is determined by interactions with residues of the acyl pocket as well as of the peripheral anionic site of AChE. , 2004, Biochemistry.

[182]  K. Cannard.  The acute treatment of nerve agent exposure , 2006, Journal of the Neurological Sciences.

[183]  A. Mukhopadhyay,et al.  Inclusion bodies and purification of proteins in biologically active forms. , 1997, Advances in biochemical engineering/biotechnology.

[184]  C. Jackson,et al.  A 5000-Fold Increase in the Specificity of a Bacterial Phosphotriesterase for Malathion through Combinatorial Active Site Mutagenesis , 2014, PloS one.

[185]  Vaibhav Upadhyay,et al.  Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process , 2015, Microbial Cell Factories.

[186]  Cerys Docx,et al.  Human plasma-derived BuChE as a stoichiometric bioscavenger for treatment of nerve agent poisoning. , 2013, Chemico-biological interactions.

[187]  A. Mohsenifar,et al.  Enhancing organophosphorus hydrolase stability by immobilization on chitosan beads containing glutaraldehyde , 2015 .

[188]  Dan S. Tawfik,et al.  Evolved stereoselective hydrolases for broad-spectrum G-type nerve agent detoxification. , 2012, Chemistry & biology.

[189]  F. Raushel,et al.  Enzymatic neutralization of the chemical warfare agent VX: evolution of phosphotriesterase for phosphorothiolate hydrolysis. , 2013, Journal of the American Chemical Society.

[190]  K. Gunsalus,et al.  Protein production and purification , 2008, Nature Methods.

[191]  D. Ollis,et al.  Use of OpdA, an organophosphorus (OP) hydrolase, prevents lethality in an African green monkey model of acute OP poisoning. , 2014, Toxicology.

[192]  H. Rüterjans,et al.  Role of calcium ions in the structure and function of the di-isopropylfluorophosphatase from Loligo vulgaris. , 2001, The Biochemical journal.

[193]  A. Forlino,et al.  Human recombinant prolidase from eukaryotic and prokaryotic sources , 2006, The FEBS journal.

[194]  P. Eyer,et al.  Reappraisal of indications and limitations of oxime therapy in organophosphate poisoning , 1997, Human & experimental toxicology.

[195]  J. Borak,et al.  Chemical warfare agents: II. Nerve agents. , 1992, Annals of emergency medicine.

[196]  B. Schoenborn,et al.  Neutron structure and mechanistic studies of diisopropyl fluorophosphatase (DFPase). , 2010, Acta crystallographica. Section D, Biological crystallography.

[197]  F. Raushel,et al.  Three-dimensional structure of the binuclear metal center of phosphotriesterase. , 1995, Biochemistry.

[198]  David R. Liu,et al.  Methods for the directed evolution of proteins , 2015, Nature Reviews Genetics.

[199]  K. Kehe,et al.  Limitations and challenges in treatment of acute chemical warfare agent poisoning. , 2013, Chemico-biological interactions.

[200]  Paul J. Plummer,et al.  A comparative analysis of methylome profiles of Campylobacter jejuni sheep abortion isolate and gastroenteric strains using PacBio data , 2015, Front. Microbiol..

[201]  M. Nagao,et al.  Definitive evidence for the acute sarin poisoning diagnosis in the Tokyo subway. , 1997, Toxicology and applied pharmacology.

[202]  Y. Ashani,et al.  Enzymes as pretreatment drugs for organophosphate toxicity , 1991, Neuroscience & Biobehavioral Reviews.

[203]  J. McDonough,et al.  Anticonvulsants for Nerve Agent-Induced Seizures: The Influence of the Therapeutic Dose of Atropine , 2007, Journal of Pharmacology and Experimental Therapeutics.

[204]  E. Albuquerque,et al.  Molecular and Cellular Actions of Galantamine: Clinical Implications for Treatment of Organophosphorus Poisoning , 2009, Journal of Molecular Neuroscience.

[205]  Rupa Iyer,et al.  Protein engineering of representative hydrolytic enzymes for remediation of organophosphates , 2015 .

[206]  F. Raushel,et al.  Enhancement, relaxation, and reversal of the stereoselectivity for phosphotriesterase by rational evolution of active site residues. , 2001, Biochemistry.

[207]  W. Wang,et al.  Lyophilization and development of solid protein pharmaceuticals. , 2000, International journal of pharmaceutics.